8-K: Intelligent Bio Solutions Inc. Announces Impressive 148% Revenue Growth for Fiscal Year 2024

Intelligent Bio Solutions Inc. reports a substantial 148% year-over-year revenue increase for fiscal year 2024, driven by strong demand for its non-invasive drug testing solutions.

Summary

• Intelligent Bio Solutions Inc. (INBS) has released preliminary unaudited revenue results for the fiscal fourth quarter and full year ended June 30, 2024.
• The company reported revenue of $0.73 million for the fourth quarter and $3.11 million for the full fiscal year.
• This represents a 64% increase in revenue for the fourth quarter compared to the same period in 2023 and a 148% increase for the full fiscal year compared to 2023.
• INBS also anticipates a 20% increase in cartridge sales and a 26% increase in reader sales for the fiscal year ended June 30, 2024, compared to the prior fiscal year.
• The company attributes this growth to increased market demand, brand awareness, and customer base expansion.
• The reader install base has grown to over 1000 readers, with over 400 active customer accounts.
• The company is focusing on safety-critical industries such as construction, manufacturing, transportation, and warehousing and logistics.
• INBS expects to disclose full financial results in its upcoming Annual Report on Form 10-K, expected to be filed during the week commencing September 16, 2024.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to the exceptionally high revenue growth, strong sales figures, and optimistic outlook. The company's performance is significantly above industry averages, suggesting a strong market position and future potential.

Positives

• The company experienced significant revenue growth, with a 148% increase year-over-year for the full fiscal year.
• There was a substantial increase in both cartridge and reader sales, indicating strong product adoption.
• The company's customer base is expanding, with over 400 active accounts.
• The reader install base has grown to over 1000 readers, creating a recurring revenue stream from cartridge sales.
• The company is targeting high-growth sectors with a clear need for their testing solutions.

Risks

• The preliminary unaudited revenue results are subject to adjustments based on the company's completion of its year-end financial close process.
• The company's future success depends on its ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals.

Future Outlook

The company is optimistic about future growth opportunities and expects to continue expanding its customer base and market reach within safety-critical industries and new geographic regions. They are entering fiscal year 2025 from a sound financial and operational position.

Management Comments

• Spiro Sakiris, CFO of INBS, stated that the company has delivered strong preliminary results for the fiscal fourth quarter and full year.
• Spiro Sakiris also noted that the growing number of active customer accounts indicates that the product resonates with customers.
• Harry Simeonidis, President and CEO of INBS, highlighted the company's focus on industries such as construction, manufacturing, transportation, and warehousing and logistics.
• Harry Simeonidis also mentioned that partnerships in new regions have expanded the company's reach.

Industry Context

The announcement reflects a growing demand for rapid, non-invasive drug testing solutions, particularly in safety-critical industries. This aligns with broader trends in workplace safety and the increasing adoption of technology for drug screening.

Comparison to Industry Standards

• While specific competitor data is not provided in the document, a 148% year-over-year revenue growth is exceptionally high compared to typical growth rates in the medical technology sector.
• Companies like Abbott Laboratories and Danaher Corporation, which are large players in the diagnostics space, typically see single-digit or low double-digit growth rates.
• Smaller, more specialized companies in the point-of-care testing market might experience higher growth rates, but 148% is still a very strong performance.
• The 20% and 26% growth in cartridge and reader sales respectively, also indicates strong market traction compared to industry averages.

Stakeholder Impact

• Shareholders will likely view the strong revenue growth positively.
• Employees may benefit from the company's growth and success.
• Customers in safety-critical industries will have access to innovative drug testing solutions.
• Suppliers may see increased demand for their products and services.

Next Steps

• The company will file its Annual Report on Form 10-K during the week commencing September 16, 2024.
• The company will continue to focus on expanding its customer base and market reach within safety-critical industries and new geographic regions.

Key Dates

Keywords

drug testing, non-invasive testing, medical technology, revenue growth, fingerprint analysis, biosensor, cartridge sales, reader sales, safety-critical industries